Literature DB >> 22226102

GVHD prevention: an ounce is better than a pound.

Pavan Reddy1, Gérard Socié, Corey Cutler, Daniel Weisdorf.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22226102      PMCID： PMC3573530          DOI： 10.1016/j.bbmt.2011.10.034

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  64 in total

Review 1.  Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.

Authors:  D H Fowler; R E Gress
Journal:  Leuk Lymphoma       Date:  2000-07

Review 2.  Thymic development and peripheral homeostasis of regulatory T cells.

Authors:  Adrian Liston; Alexander Y Rudensky
Journal:  Curr Opin Immunol       Date:  2007-02-15       Impact factor: 7.486

3.  Naive and memory T cells induce different types of graft-versus-host disease.

Authors:  Suparna Dutt; Diane Tseng; Joerg Ermann; Tracy I George; Yin Ping Liu; Corrine R Davis; C Garrison Fathman; Samuel Strober
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

4.  Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease.

Authors:  Yanhui Xu; Andrew S Flies; Dallas B Flies; Gefeng Zhu; Sudarshan Anand; Sarah J Flies; Haiying Xu; Robert A Anders; Wayne W Hancock; Lieping Chen; Koji Tamada
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

5.  TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x bm12)F1 mice.

Authors:  Geri R Brown; Ed Lee; Dwain L Thiele
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

Review 6.  Cytolytic pathways in haematopoietic stem-cell transplantation.

Authors:  Marcel R M van den Brink; Steven J Burakoff
Journal:  Nat Rev Immunol       Date:  2002-04       Impact factor: 53.106

7.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

8.  Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets.

Authors:  B Nikolic; S Lee; R T Bronson; M J Grusby; M Sykes
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

9.  A uniform genomic minor histocompatibility antigen typing methodology and database designed to facilitate clinical applications.

Authors:  Eric Spierings; Jos Drabbels; Matthijs Hendriks; Jos Pool; Marijke Spruyt-Gerritse; Frans Claas; Els Goulmy
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

10.  Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Petra Hoffmann; Joerg Ermann; Matthias Edinger; C Garrison Fathman; Samuel Strober
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307
View more
  5 in total

1.  Immune Suppression in Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Thomas F Michniacki; Sung Won Choi; Daniel C Peltier
Journal:  Handb Exp Pharmacol       Date:  2022

Review 2.  Mouse models in bone marrow transplantation and adoptive cellular therapy.

Authors:  Caroline Arber; Malcolm K Brenner; Pavan Reddy
Journal:  Semin Hematol       Date:  2013-06-11       Impact factor: 3.851

3.  Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single-center cohort study.

Authors:  Jérémie Héritier; Michael Medinger; Dominik Heim; Helen Baldomero; Christian Arranto; Jörg P Halter; Jakob R Passweg; Martina Kleber
Journal:  Bone Marrow Transplant       Date:  2022-02-08       Impact factor: 5.483

4.  Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.

Authors:  Hui Liu; Xiao Zhai; Zhaoyang Song; Jing Sun; Yang Xiao; Danian Nie; Yu Zhang; Fen Huang; Hongsheng Zhou; Zhiping Fan; Sanfang Tu; Yonghua Li; Xutao Guo; Guopan Yu; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-02-08       Impact factor: 17.388

5.  Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease.

Authors:  Ludovic Belle; Gilles Fransolet; Joan Somja; Marilène Binsfeld; Philippe Delvenne; Pierre Drion; Muriel Hannon; Yves Beguin; Grégory Ehx; Frédéric Baron
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.